Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
At Delee, we aim to radically change the way cancer is detected, monitored and tre...
At Delee, we aim to radically change the way ca...
Smilelove offers clear aligner treatments direct-to-consumer: no expensive appoint...
Smilelove offers clear aligner treatments direc...
So-Young International Inc. (NASDAQ: SY) (âSo-Youngâ or the âCompanyâ) is ...
So-Young International Inc. (NASDAQ: SY) (âSo...
We are a network of full-service medical equipment companies that use tailored pro...
We are a network of full-service medical equipm...
BASi provides drug discovery and development services and analytical instruments t...
BASi provides drug discovery and development se...
Veracyte is a leading genomic diagnostics company that is fundamentally improving ...
Veracyte is a leading genomic diagnostics compa...
Omeros is a commercial-stage biopharmaceutical company committed to discovering, d...
Omeros is a commercial-stage biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.